`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________________
`
`MYLAN PHARMACEUTICALS INC.,
`TEVA PHARMACEUTICALS USA, INC. and AKORN INC.,1
`Petitioners,
`v.
`ALLERGAN, INC.
`Patent Owner.
`
`_____________________________
`
`Case IPR2016-01127 (8,685,930 B2)
`Case IPR2016-01128 (8,629,111 B2)
`Case IPR2016-01129 (8,642,556 B2)
`Case IPR2016-01130 (8,633,162 B2)
`Case IPR2016-01131 (8,648,048 B2)
`Case IPR2016-01132 (9,248,191 B2)
`_____________________________
`
`PETITIONER MYLAN PHARMACEUTICALS INC.’S
`MANDATORY CHANGE-OF-INFORMATION NOTICES
`
`
`1 Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-
`00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599,
`IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601,
`have respectively been joined with the captioned proceedings. The word-for-word
`identical paper is filed in each proceeding identified in the caption pursuant to the
`Board’s Scheduling Order (Paper 10).
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), the undersigned on behalf of and acting
`
`in a representative capacity for Petitioner Mylan Pharmaceuticals Inc. (“Mylan”),
`
`hereby submits the following mandatory change-of-information notices in
`
`connection with the inter partes reviews identified in the caption.
`
`A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Unchanged
`
`B. Related Matters (37 C.F.R. § 42.8(b)(2)) – Revised
`
`Allergan, Inc. v. Teva Pharm. USA, Inc., No. 2018-1130 (Fed. Cir.)
`
`(invalidity affirmed November 13, 2018) (EX1163-65; EX1172);
`
`Allergan, Inc. v. Deva Holding A.S., No. 2:16-cv-1447 (E.D. Tex.) (filed
`
`December 22, 2016);
`
`Allergan, Inc. v. Saptalis Pharmaceuticals, LLC, No. 1:18-cv-01231 (D.
`
`Del.) (suit asserting ’162 and ’556 patents voluntarily dismissed January 3, 2019)
`
`(updated);
`
`Allergan, Inc. v. Amneal Pharmaceuticals LLC, No. 1:18-cv-01457 (D. Del.)
`
`(suit asserting ’162 and ’556 patents voluntarily dismissed January 3, 2019)
`
`(updated);
`
`St. Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc., No. 2018-1638
`
`(Fed. Cir.) (mandate issued November 20, 2018) (updated);
`
`St. Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc., No. 18-___ (U.S.)
`
`(petition for certiorari filed December 20, 2018) (updated); and
`
`
`-1-
`
`
`
`U.S. Patent Application No. 15/585,320 (restriction requirement entered
`
`July 5, 2018).
`
`C. Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) – Unchanged
`
`
`
`D. Electronic Service – Unchanged
`
`
`
`Dated: January 7, 2019
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
` Steven W. Parmelee
` Reg. No. 31,990
`
`
`
`
`
`-2-
`
`
`
`CERTIFICATE OF SERVICE
`This is to certify that I caused to be served a true and correct copy of the
`
`
`
`foregoing Petitioner Mylan Pharmaceuticals Inc.’s Mandatory Change-of-
`
`Information Notices on this 7th day of January, 2019, on the Patent Owner at the
`
`correspondence address of Allergan, Inc. and St. Regis Mohawk Tribe as follows:
`
`Dorothy P. Whelan
`Michael Kane
`Susan Morrison Colletti
`Robert M. Oakes
`Jonathan Singer
`Fish & Richardson P.C.
`3200 RBC Plaza
`60 South Sixth Street
`Minneapolis, MN 55402
`Email: IPR13351-0008IP1@fr.com
`Email: IPR13351-0008IP2@fr.com
`Email: IPR13351-0008IP3@fr.com
`Email: IPR13351-0008IP4@fr.com
`Email: IPR13351-0008IP5@fr.com
`Email: IPR13351-0008IP6@fr.com
`Email: PTABInbound@fr.com
`
`Alfonso Chan
`Joseph DePumpo
`Michael W. Shore
`Christopher L. Evans
`Shore Chan DePumpo LLP
`901 Main Street, Suite 3300
`Dallas, TX 75201
`Email: achan@shorechan.com
`Email: jdepumpo@shorechan.com
`Email: mshore@shorechan.com
`Email: cevans@shorechan.com
`
`-3-
`
`
`
`And on the remaining petitioners as follows:
`
`
`Gary Speier
`Mark Schuman
`Ralph Wilson Powers III
`CARLSON, CASPERS, VANDENBURGH,
`LINDQUIST & SCHUMAN, P.A.
`225 South Sixth Street, Suite 4200
`Minneapolis, MN 55402
`Email: gspeier@carlsoncaspers.com
`Email: mschuman@carlsoncaspers.com
`Email: IPRCyclosporine@carlsoncaspers.com
`Email: tpowers-PTAB@sternekessler.com
`Email: PTAB@sternekessler.com
`
`Attorneys for Teva Pharmaceuticals USA, Inc.
`
`Michael Dzwonczyk
`Mark Boland
`SUGHRUE MION, PLLC
`2100 Pennsylvania Ave., NW
`Washington, DC 20037
`Email: mdzwonczyk@sughrue.com
`Email: mboland@sughrue.com
`Attorneys for Akorn Inc.
`
`
`
`Dated: January 7, 2019
`
`
`
`
`
`
`Respectfully submitted,
`
`/ Steven W. Parmelee /
` Steven W. Parmelee, Lead Counsel
` Reg. No. 31,990
`
`
`
`
`
`-4-
`
`